HOOKIPA CMO resigns; Schlienger and Necina promoted effective July 1

HOOKIPA Pharma Inc.

CMO Igor Matushansky resigns effective June 30, 2022; will chair Scientific Advisory Board.
Katia Schlienger promoted to EVP Clinical Development, joins Executive Team.
Roman Necina appointed Chief Development Officer, integrating manufacturing and project management.
Gilead registration rights agreement filed; Gilead may purchase up to $35M in common stock; initial $5M at $3.00/share.

item 1.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Igor Matushansky

Chair of Scientific Advisory Committee

HOOK · HOOKIPA Pharma Inc.

Filed: June 22, 2022, 7:59 PM ET

Dr. Matushansky was also appointed to chair the Company’s newly formed Scientific Advisory Committee.

Departed

Igor Matushansky

Chief Medical Officer and Global Head of Research and Development

HOOK · HOOKIPA Pharma Inc.

Effective: 2022-06-30
Filed: June 22, 2022, 7:59 PM ET

On June 20, 2022, Igor Matushansky, M.D., Ph.D., who has served as the Chief Medical Officer and Global Head of Research and Development of the Company, notified the Company that he will resign from his current positions, effective as of June 30, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.9

Igor Matushansky was appointed as Chair of Scientific Advisory Committee at HOOKIPA Pharma Inc..

Action: appointed
Role: Chair of Scientific Advisory Committee

Exact text from the filing

Dr. Matushansky was also appointed to chair the Company’s newly formed Scientific Advisory Committee.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Igor Matushansky resigned as Chief Medical Officer and Global Head of Research and Development at HOOKIPA Pharma Inc..

Action: resigned
Role: Chief Medical Officer and Global Head of Research and Development

Exact text from the filing

On June 20, 2022, Igor Matushansky, M.D., Ph.D., who has served as the Chief Medical Officer and Global Head of Research and Development of the Company, notified the Company that he will resign from his current positions, effective as of June 30, 2022.

View on SEC.gov

HOOKIPA Pharma Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-073084

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.